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Introduction
Several fundamental advancements have been devel-
oped both in embolic protection systems and in technical 
approaches to reduce the perioperative stroke rates as-
sociated with carotid stenting [1–6]. Those developments 
have been recently reinforced by the progress in carotid 
stent design [7] that today allows to effectively seques-
trate the atherosclerotic plaque, minimizing intra-pro-
cedural and preventing post-procedural embolism (sec-
ond-generation carotid stents, mesh-covered stents) [8]. 
Transcervical carotid artery stenting under transient flow 
reversal is a  surgical technique that entered its clinical 
use nearly 2 decades ago [3–5]. Recently, the technique 
has gained a new momentum with an accumulating da-
ta-based realization of its two fundamental advantages: 
(1) robust cerebral protection by flow reversal is opera-
tional against embolism even prior to any endovascular 
approach to the lesion (i.e., ‘protected’ lesion crossing), 
is continuous, and is highly effective throughout the pro-
cedure, and (2) avoiding cerebral embolism associated 
with aortic arch cannulation [3–5, 9]. Accumulating re-
sults from transcarotid artery revascularization (TCAR, 
using the EnRoute flow reversal system, Silk Road) stud-
ies show low stroke/death rates comparable to carotid 
endarterectomy while maintaining the minimally inva-
sive benefits of carotid stenting [10, 11]. The transcervical 
approach, which circumvents a  number of embolic-risk 
maneuvers inherent to transfemoral carotid stenting, 
and with its highly effective proximal cerebral protection 
[9], has a strong potential to become, in surgical hands 
at least (as the system requires surgical, rather than per-
cutaneous, exposure of the common carotid artery, CCA), 
the preferred method of carotid artery stenting (CAS) in 
the near future. Paired with the progress in carotid stent 
technology [7, 12], it may well challenge carotid endar-
terectomy (CEA) as the carotid artery revascularization 
method of choice not only in standard-risk lesions, but 
also in symptomatic and highly emboligenic lesions [11]. 
Our experience, over the years, involved a high-pro-
portion proximal cerebral protection use [6, 13–15] and it 
also involved our introduction [16] and every-day clinical 
practice all-comer patient-and-lesion evaluation [15–17] 
of the MicroNET-covered embolic prevention stent. As an 
International ‘TCAR Center of Excellence’ (2018) we sys-
tematically paired the TCAR system (EnRoute, Silk Road) 
with our routine use of the CGuard embolic prevention 
stent system (InspireMD) to minimize not only intra-pro-
cedural but also post-procedural cerebral embolism in 
relation to the index carotid lesion [8, 12]. This strategy 
combines, on the one hand, optimized intra-procedural 
cerebral protection with carotid plaque sequestration, 
optimized endovascular lumen reconstruction, and sus-
tained embolic prevention on the other [3–5, 9, 12]. We 
have found the TCAR system not only clinically effective 
and operator-friendly but also naturally compatible with 
the MicroNET-covered stent and hence developed a con-
cept of ‘combining the best (in carotid neuroprotection 
technology) with the best (in carotid stent technology)’ 
and steadily increased our TCAR use in high-risk and 
very high-risk patients and lesions. Unfortunately, the 
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SilkRoad TCAR system has become unavailable to us 
with the COVID-19 pandemic flight and transportation re-
strictions, prompting us to explore ways to answer a thus 
unmet, important clinical need. 
Aim
The present technical note, with its imaging and clin-
ical correlates, describes how to (1) achieve an effective 
proximal cerebral protection through a transcervical ac-
cess transient flow reversal kit based on consumables 
routine in vascular surgery and interventional vascular 
medicine, and (2) optimize its use by pairing it with the 
MicroNET-covered stent system for an effective plaque 
sequestration with endovascular lumen reconstruction 
and sustained embolic prevention. 
Material and methods
In a series of consecutive patients in whom transfem-
oral access for CAS was not feasible for anatomic rea-
sons while a minimally-invasive transcarotid intervention 
was deemed preferable over CEA (NeuroVascular Team 
decision-making), we performed transcervical CAS with 
the MicroNET-covered stent system (CGuard) under a ro-
bust transient flow reversal that was accomplished by 
employing vascular surgery and interventional vascular 
medicine routine materials and devices (Figure 1 A). The 
MicroNET-covered stent system has been characterized 
in detail previously [7, 15, 16] (see summarized informa-
tion provided in Figure 1 legend). CGuard bench testing 
demonstrated its excellent adaptability (SmartFit fea-
ture) and radial force similar to that of the Precise stent 
(Cordis) [7]. CGuard clinical and angiographic corelab 
evaluation [15] confirmed its optimal adaptability to the 
local anatomy, with an optimal technical, angiographic 
and clinical performance across the whole spectrum of 
all-comer patients and lesions (from the thrombus-con-
taining to highly-calcific [15, 17]) and indicated an ab-
sence of stent-related thrombosis and a  low restenosis 
rate [17–20]. An important feature of the CGuard system 
is the MicroNET coverage of any potential residual plaque 
prolapse between the nitinol frame struts, making it ‘pro-
tected’ (neutralized, non-embolizing) [21]. 
Diffusion-weighted magnetic resonance imaging 
(DW-MRI) was performed within 14 days before (base-
line) and within 10 days after the procedure (control). Re-
sults were evaluated for consistency. 
This work was approved by the local Ethics Commit-
tee, and all patients provided informed consent.
Results
Study patients presented with a recent left (dominant) 
hemispheric stroke (Patient 1 and Patient 4) or recent left 
(dominant) hemispheric crescendo transient ischemic 
attacks (TIAs, Patient 1 and Patient 4). They were aged 
63–76 years; women/men ratio was 1 : 1. Three patients 
had Leriche syndrome (Patient 2, Patient 3, and Patient 4) 
whereas Patient 1 had a two-vessel percutaneous coro-
nary intervention for concomitant critical coronary artery 
disease and a failed transfemoral access for CAS on the 
day before the study index procedure. The study patients 
had severe clinical heart failure (echocardiographic left 
ventricular ejection fraction of 20–35%) with prior epi-
sodes of hospitalization-requiring exacerbations (recent-
ly stable on maximized medical treatment) and/or severe 
chronic obstructive pulmonary disease (3/4 and 1/2 of 
the study group, respectively). Two had a short neck, and 
one had a  prior symptomatic (stroke) occlusion of the 
contralateral carotid artery (Patient 1, cf. Figure 2 B). Pri-
or to the procedure, the operators became familiar with 
individual anatomy specificities (detailed pre-procedural 
duplex ultrasound; in addition 2 patients presented with 
CT angiography performed in the referring hospital). Con-
sistent with our routine strategy of ‘local-first’ anesthe-
sia in transcervical CAS, all procedures were performed 
under local anesthesia. There was no clinical or technical 
need to convert to general anesthesia. 
The patients were on aspirin (75 mg o.d.), high-dose 
statin (atorvastatin 80  mg o.d. or rosuvastatin 40  mg 
o.d.), and an angiotensin-converting enzyme inhibitor 
and a β-blocker. Three patients were on a second anti-
platelet agent prior to the index procedure (clopidogrel or 
prasugrel) whereas in one, the second antiplatelet agent 
(clopidogrel 600 mg) was administered immediately after 
the procedure. Anti-hypertensive medications were with-
held on the morning of the index procedure day to in-
crease the arterial blood pressure (the procedural ‘base-
line’ arterial blood pressure of optimally 160–180 mm Hg 
if spontaneous) and thus the likelihood to enhance col-
lateral flow and, if feasible, increase the ‘back’ pressure 
[22] that constitutes the principle drive of the flow-rever-
sal neuroprotection [9, 13, 14, 23, 24]. Atropine (0.5–1 mg 
i.v.) was given routinely prior to lesion predilatation while 
unfractionated heparin was titrated to maintain the ac-
tivated clotting time (ACT) of at least 250 s [9, 14, 19] 
throughout the intervention. 
The transcervical CAS procedure in this study all per-
formed within one month. Routinely available materials 
to assemble flow reversal kits are shown in Figure 1 A. 
The CCA (surgical, and as proximal as feasible to facili-
tate the lesion no-touch technique) access is presented 
in Figure 1. Fundamental steps of surgery were according 
to the literature [3–5] and incorporated our TCAR system 
experience. An immediate post-procedural access site 
closure result is exemplified in Figure 1 B. In 2 patients 
(Patient 1 and Patient 4) endovascular CCA clamping 
was performed using the FlowGate (Stryker) or MoMa 
(Medtronic) balloon catheter. Because the role of exter-
nal carotid artery (ECA) clamping in trans-cervical flow 
reversal is debated [3–5, 23, 24], in our transcervical 
MoMa procedure we used the two-balloon version of the 
catheter (ECA and CCA). However, the ECA balloon had 
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Figure 1. Technical aspects of carotid artery lumen reconstruction using the transcervical route under transient 
flow reversal, with the MicroNET-covered stent use for plaque sequestration and sustained embolic prevention. 
A – The armamentarium, vascular access, and principles of proximal cerebral protection. a – The MicroNET-cov-
ered carotid stent consisting of a  widely open-cell nitinol frame covered, on the outside, with a  MicroNET 
sleeve. The aperture size of the mesh pores is 150–180 μm, similar to the size of pores in filters used in fil-
ter-protected CAS. The open-cell stent frame strut thickness is 0.24 mm and the nitinol frame open-cell area 
is 21.66 mm2 (i.e., the largest among open-cell carotid stents). The closed cell, proprietary MicroNET is made 
of a single-knitted PET fiber of 20 μm in thickness, forming mesh cells of only 0.023–0.032 mm2, i.e., the most 
dense closed-cell area among contemporary stents. The system is available in a typical range of lengths (20 
to 60 mm) and diameters (6 to 10 mm). b – Flow reversal armamentarium: The initial arterial access sheath 
(‘Acc’, 4F or 5F), the working sheath (‘Art’, 8F or 9F) with the needle (‘N’) and a wire (‘W’), flow reversal oper-
ation central stopcock with a handle (red arrow), 3-port manifold (blood pressure port, ‘BP’, 0.9% heparinized 
saline port, ‘Sal’, and a contrast port, ‘Co’), the filter (‘F’; here – a blood transfusion filter with a modified inflow 
spike tip to enable harboring potentially large embolic particles) connected at the outflow end to the venous 
sheath (‘V’). An additional 20 ml aspiration syringe (‘As’) may be connected either at the venous sheath side 
tubing stopcock (such a placement of ‘As’ prevents inadvertent re-aspiration of the filter-captured debris to the 
syringe and their erroneous passage back to the arterial line) or directly at the central stopcock (cf. simplified 
set-up in Figure 1B-j that does not involve intra-arterial blood pressure monitoring and a manifold, but a sin-
gle-syringe port that can harbor, depending on the procedural step, either a contrast syringe or a saline syringe 
or an aspiration syringe). Note that we manually pre-shape arterial sheaths to improve coaxial alignment to 
the CCA lumen and reduce the artery dissection risk. In the case of tunneling (cf. c, ‘Tu’) that is highly advisable 
for a maximally co-axial alignment of the working sheath in the case, in particular, of a deep positioning of the 
common carotid artery and/or a short neck, the standard (short) access needle needs to be replaced with a lon-
ger one. c – The common carotid artery (CCA) sheath entry site; display of a deep anatomic positioning of the 
artery that explains the role of tunneling for a maximally co-axial sheath alignment. This example illustrates 
why the trans-cervical access is, at least with the current technology, a routinely surgical rather than percuta-
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neous access. Surgical CCA exposure and access allow a controlled closure of the CCA entry site with a suture 
and direct hemostasis control, allow the access angle improvement; all in all, the risk of inadvertent events 
such as puncture of the CCA posterior wall or of other vessels in the vicinity and the risk of the artery access 
site bleeding is minimized (see also Figure 1 B–a and 1 B–b). Furthermore, surgical cutdown and CCA exposure 
is mandatory in the case of performing surgical (rather than endovascular, cf. Patient 1 and Patient 4) clamping 
of the CCA using a tourniquet (the green arrow in Figure 1B–a and 1B–b; cf. Patient 2 and Patient 3 in Figure 2). 
Endovascular part of the procedure – insertion of the lesion predilatation balloon, under flow reversal, through 
the Y connector that is linked either directly to the working sheath side arm tubing (in the case of surgical 
CCA clamping; cf. Patient 1 and Patient 4 in Figure 2 A) or to the balloon catheter Y connector (in the case of 
endovascular clamping; cf. Patient 2 and Patient 3 in Figure 2 A). The red arrow illustrates positioning of the 
central stopcock, with the arterial sheath side tube flow directed exclusively to the femoral vein (example in 
Figure 1 B–d) through a filter (not shown in Figure 1 A–d that is a zoom on the Y connector visible on the right 
side of the image, the central stop-cock (red arrow). Dotted arrows indicate flow direction. See Figure 2 A for 
corresponding angiographic images. B – Technical aspects of the procedure; (a) and (b) illustrate the impor-
tance of tunneling (‘Tu’) in the case of the deep anatomical location of CCA and/or short neck and/or short 
CCA with a low positioning of the bifurcation; (c) shows the importance of the sheath manual pre-shaping to 
maximize alignment with the CCA lumen; (d) illustrates the redundant balloon catheter length when using the 
balloon catheters of length that enables transfemoral access to CCA (such as FlowGate, Stryker, in (d) or MoMa, 
Medtronic, in (e)), indicating the need for customization (shortening) that would have the additional benefi-
cial effect of reducing flow resistance; (e) demonstrates the working set-up, with the central 3-way stopcock 
connected, on the one side, to the MoMa catheter Y connector, on the other to 3-tap manifold (in this setup 
a BP line, 0.9% NaCl line, and the contrast line), and on the third port – to the filter entry port. Inflating the CCA 
balloon of the MoMa catheter (inflation syringe, ‘Infl’) will result in flow cessation, with the ‘back’ pressure 
value that can be read on the monitor screen (see (g)). Turning the handle of the central stopcock 90° clockwise 
will result a brisk reverse flow driven by the ‘back’ pressure of, in this case, 55/42 mm Hg. The saline in the 
tubing by the filer entry port (‘sal’) will be spontaneously pushed into the filter by the blood coming from the 
brain, with the deposit of any plaque embolic debris in the filter. The emboli-filtered blood then spontaneously 
returns, via the filter exit port, through the tubing to the venous sheath side arm (‘Ven’ shown in (d)) to the 
venous circulation of the patient. Principal limiting factors of the flow reversal robustness are the ‘back’ pres-
sure generated by the cerebral collateral circulation (that is an anatomy-driven factor not modifiable other than 
increasing the systemic pressure), the diameter of the tubing as well as and any other potential ‘bottlenecks’ 
in the circuit, the total length of the access catheters (if used) and the tubing (both should not be longer than 
needed), and the stenosis severity (until effectively predilated). The latter is not a factor relevant for the oper-
ating capacity of the flow reversal protection because any debris mobilized with predilatation will get robustly 
moved to the filter with increased back flow resulting from relieving the stenosis severity. Dotted red arrows 
indicate flow direction. (f) and (g) are the ECG (green trace) and invasive blood pressure (red trace) monitoring 
at baseline (f) and during flow reversal (g). The ‘back’ pressure of, in this case, 55/42 mm Hg is the force that 
drives reversed flow from the arterial to the venous circulation (in our setup, the femoral vein though other 
large veins, such as jugular vein may also be used) through a filter-containing temporal (intraprocedural) fistula 
setup. (h) is the moment of turning the central stop-cock handle 90° clockwise, resulting in a robust flow from 
the diseased ICA towards the femoral vein; the reversed flow briskly replaces (i) the saline in the tubing (Sa) 
with the blood (Bl) that from now on carries to the filter (cf. Figure 2 B) any athero-thrombotic embolic debris 
generated with lesion crossing, predilatation and stent insertion (cf. Figure 2 A). (j) is a simplified version of the 
system, with the arteriovenous flow directly from the sheath side arm tubing, through the central stopcock, to 
the filter and then to the side arm of the venous sheath. With this simplified setup, there is no ‘back’ pressure 
monitoring. Each individual syringe needed at the particular stage of the procedure (i.e., saline syringe, contrast 
syringe, aspiration syringe) gets connected directly to the central stopcock (red arrow). The point captured in (j) 
is the moment of transferring the blood from the operated artery (that has just been aspirated to the syringe), 
through the filter, to the femoral vein. (k) and (l) are typical immediate post-procedural results after surgical 
closure of the arterial access site, yielding, with the location of the cut, an optimal cosmetic result (‘Re’ is Redon 
drain). The skin incision length may be routinely reduced to ≈2 cm [2] according to local anatomic conditions 
and surgeon’s preferences. The long-term cosmetic effect, with the incision site in a natural anatomic line is 
barely visible, and it is significantly superior to that of conventional CEA; in addition skin sensation in the neck 
is normal that has a very practical role, for instance, during shaving [34]
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Figure 2. Angiography, cerebral ischemia imaging, and the flow reversal filter material in transcervical ca-
rotid artery stenting under flow reversal. A – Angiography at fundamental stages of the procedure. The top 
panel shows baseline angiographic images after establishing vascular access (cf. Figure 1) in four consecu-
tive patients with sub-acutely symptomatic internal carotid artery stenosis (Duplex images were consistent 
with a thrombus-containing tight ICA lesion in all subjects, Patient 1 had a tandem stenosis). All patients are 
left-hemispheric dominant, and the symptom-causing lesion was in the left internal carotid artery (LICA). Two 
patients (Patient 1 and Patient 4) presented with subacute (≤ 14 days) left-hemispheric stroke (cf. Figure 2 B); 
two other subjects had crescendo TIAs that were presumed to be hemodynamic due to a very high lesion sever-
ity on Duplex imaging (baseline diffusion-weighted imaging provided evidence for concomitant spontaneous 
plaque embolism, cf. Figure 2 B). The second panel from the top illustrates lesion crossing and predilatation 
under flow reversal (red arrows). CCA clamping was endovascular in Patient 1 and Patient 4 (see inflated CCA 
balloons in the bottom of the images in Patient 1 and Patient 4, FlowGate and MoMa, respectively) and surgical 
(tourniquet; cf. Figure 1) in Patient 2 and Patient 3. In all cases the guidewire was WhisperMS 0.014’. Predila-
tation (insets) was performed using coronary balloons of 3.5 mm, 3.5 mm, 4.0 mm and 3.0 mm, respectively 
at 10–12 atm. Backward washout of the contrast upon lesion predilatation (compare images in the third panel 
with those in the second panel) is consistent with an effective spontaneous transport of any debris to the fil-
ters that are shown in Figure 2 B. The second panel from the bottom shows stent placement and implantation 
under continued flow reversal (CGuard 9.0 × 40 mm, CGuard 9.0 × 30 mm, CGuard 10.0 × 30 mm, and CGuard 
9.0 × 30 mm respectively), as well as (insets) sequential post-dilatation optimizations of the stents that we 
perform routinely (6.5 mm balloon in Patient 1, 6.0 mm balloon in Patient 2, and 5.5 mm balloon in Patient 
3 and Patient 4). Final angiographic results of the procedures are demonstrated in the bottom panel, consis-
tent with a full, optimal endovascular reconstruction of the lumen of the artery with 0% residual stenosis in 
all cases, full patency of the branches, and a full respect of the anatomy (note the SmartFIT characteristics 
of the stent – self-adjustment of the widely open nitinol frame, with an adequate ‘self-tapering’ in case of 
a significant ICA/CCA diameter mismatch – best illustrated in Patient 3, alleviating a need for any ‘tapered’ 
versions of the device; for the final stent images see the insets). B – Cerebral imaging at the point of subacute 
clinical symptoms triggering referrals for revascularization, and the post-procedural controls. The top panel is 
diffusion-weighted magnetic resonance (DW-MRI) cerebral imaging at the point of symptoms that triggered 
intervention (revascularization was, in all cases, within 14 days), illustrating acute/subacute lesions in all pa-
tients. Small embolic foci are depicted with thin arrows whereas thick arrows indicate relatively large ischemic 
zones that were consistent with clinically significant, lasting stroke symptoms. The second panel from the top 
shows cerebral angiography prior to the symptomatic carotid artery revascularization (injections directly via 
the CCA sheath). Patient 1 (a physician) had undergone a symptomatic occlusion of the right internal carotid 
artery 4 years earlier. The middle panel shows post-procedural photographs of the filters that were part of the 
flow reversal temporal arteriovenous fistula (shunt) circuit in these patients (cf. Figure 1). Flow reversal, as 
our default procedure strategy in such patients, taken together with the lesion ‘no touch’ strategy until flow 
reversal establishment, enabled a 100% effective protection of the brain against the plaque material in all 
subjects (see control cerebral images in the bottom for comparison with the baseline images). Absence of any 
new post-procedural lesions on DW-MRI images is consistent with an effective capture of all embolic debris in 
the filters. The fourth panel from the top is post-procedural cerebral angiograms that are consistent with a nor-
malized ipsilateral cerebral supply in all cases (in Patient 1 note also a marked improvement of the collateral 
supply to the right hemisphere). The bottom panel presents control DW-MRI images that were acquired within 
3-10 days after revascularization. In Patient 4, 1.5T scanner was used for baseline DW-MRI imaging whereas the 
control scan was performed with 3T (the 1.5T scanner was not operational at the point of control imaging). Note 
that optimal intraprocedural cerebral protection by transient flow reversal, combined with an effective plaque 
containment by the MicroNET-covered second-generation carotid stent (embolic prevention) resulted in a total 
absence of peri-procedural cerebral embolism that is an established surrogate for peri- and post-procedural 
stroke risk in relation to the index lesion [35]
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to be placed distally due to the fixed distance between 
the CCA and ECA balloon in the MoMa system (which is 
in contrast to the former Parodi Anti-Emboli System or 
the Gore Flow Reversal system with the ECA balloon in-
dependent of the CCA balloon, allowing individual anat-
omy-specific adjustment of the CCA and ECA balloon po-
sitioning with an increased likelihood of excluding ECA 
proximal branch(es) [13].
Anatomical considerations and technical aspects of 
the procedure (including routine off-the-shelf consum-
ables that we used to assemble filter-containing flow re-
versal shunts between the operated carotid artery lumen 
and a  femoral vein) are presented in Figure 1. Figure 2 
shows angiographic documentation of the procedures 
with the wire, balloon, and stent data provided in the 
Figure 2 legend. Flow reversal duration was respective-
ly 4 min 20  s, 5 min 10  s, 6 min 20  s and 6 min 50  s 
(5  min 40  s on average). Index ICA flow reversal was 
well-tolerated in the study cohort, except for a transient 
intolerance (in the last ≈90  s of the procedure) in the 
patient with contralateral ICA occlusion (Patient 1, the 
procedure was continued normally and the intolerance 
symptoms resolved upon restitution of antegrade flow). 
There were no clinical or technical complications, and all 
cases showed an excellent angiographic result consis-
tent with optimal reconstruction of the diseased vessel 
(Figure 2 A). The results were consistent across the dif-
ferent patients and the different mode of CCA clamping 
– surgical (via tourniquet, Figure 1) or endovascular (via 
inflation of the CCA balloon, Figures 1 2). In the patient 
concluding the present series, the procedure was final-
ized with intravascular ultrasound (IVUS) control of the 
lumen reconstruction quality. IVUS demonstrated a  full 
stent expansion and its excellent apposition in absence 
of any plaque prolapse. The residual area stenosis was 
negligible (8%); there was a  full, optimal endovascular 
reconstruction of the diseased vessel lumen. 
The filters used in the shunt contained embolic mate-
rial in all cases (Figure 2 B). The embolic material capture 
was 100% effective as control DW-MRI scans (Figure 2 B) 
showed absence of any new embolism. There was a nat-
ural evolution of the cerebral index infarcts in Patient 1 
and Patient 4 that had caused clinical stroke symptoms 
prompting urgent referral for carotid revascularization. 
The small embolic pre-procedural DW-MRI lesions in Pa-
tient 2, Patient 3 and Patient 4 were no longer detectable 
on the control scans (and they were also not visible on 
control FLAIR imaging). Evaluation of cerebral flow evo-
lution in relation to DW-MRI imaging confirmed a com-
bination of embolic and hemodynamic cerebral injury 
as mechanisms underlying presenting symptoms [25]. 
Thus the embolic debris collected in filters (Figure 2 B) 
confirmed the highly emboligenic characteristics of the 
carotid plaques in the study patients as indicated by the 
clinical characteristics (highly symptomatic lesions) and 
the Duplex and angiographic lesion imaging in relation to 
the baseline cerebral DW-MRI scans (Figure 2). Neurolog-
ic examination at 24–48 h post-procedurally revealed no 
new deficits. On day 3 or 4 post-procedurally the patients 
were discharged home (Patient 1, Patient 2 and Patient 3) 
or to a  stroke rehabilitation centre as pre-arranged by 
the referring hospital (Patient 4). Discharge Duplex Dop-
pler showed a normal stent lumen and normal in-stent 
velocities in all cases. Routine post-discharge evaluation 
was performed in the vascular surgery outpatient clinic 
at 10–14 days and was normal. Duplex and clinical fol-
low-up, including neurologic examination, are scheduled 
at 30 days and then yearly. Follow-up DW-MRI examina-
tions are scheduled at 90 days. 
Discussion
The first fundamental finding from this work is that 
performing transcervical CAS with minimally-invasive 
surgical access (surgical exposure of the CCA) and tran-
sient flow reversal employing routinely available off-the-
shelf sheaths and/or catheters and other materials (such 
as stopcocks, manifolds, tubing, and blood-compatible 
filters) is feasible and is relatively simple and uncompli-
cated for operators with experience in transcervical ac-
cess and experience in CAS. Another finding is that this 
approach, similar to standard TCAR, appears to perform 
very well technically and clinically with the state-of-the-
art second-generation carotid stent (MicroNET-covered 
stent, CGuard). This is important because the use of con-
ventional (first-generation, single-layered) carotid stents 
in TCAR (that provides an optimal cerebral protection but, 
nevertheless, the one that is limited to the revasculariza-
tion procedure) does not protect against post-procedural 
embolism and strokes [10, 11, 26, 27]. This shortcoming is 
consistent with the relationship between the first-gener-
ation stent plaque prolapse and post-procedural DW-MRI 
embolism and strokes that are not prevented by a classic 
single-layer closed-cell design [8, 12, 28–30]. Conversely, 
the MicroNET-covered stent provides a clinically effective 
plaque sequestration and vessel healing that is free of 
plaque prolapse-related cerebral embolism, and an op-
timal post-procedural embolic prevention in absence of 
any thrombosis or restenosis excess [17–19, 30, 31]. While 
larger patient series and longer follow-up periods are 
needed, accumulating multi-centric data indicate vascu-
lar and clinical durability of the CGuard reconstruction of 
normal carotid anatomy [17–19, 30, 31]. 
A combination of minimally-invasive (surgical) direct 
cervical access, optimized intra-procedural cerebral pro-
tection by transient flow reversal using a  filter-assist-
ed arteriovenous shunt, and sustained post-procedural 
embolic prevention using a MicroNET-covered stent may 
well become a new standard of care in symptomatic [1, 
8] or increased-risk [32] carotid stenosis patients. This 
minimally invasive approach, ‘combining the best with 
best’ appears at an immediate line to be ideal for pa-
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tients at increased risk for CEA who are not suitable 
for transfemoral access. This is particularly relevant as 
the use of large-bore flow clamping/reversal catheters 
through the transradial route is debatable because of an 
increased risk of the radial artery damage, its elimination 
as a potential arterial graft [33], and an increased risk of 
the radial access patency loss. The strategy described in 
the present communication may well be applied to oth-
er high-risk patient groups [33] and it has the potential 
to become the patient-preferred strategy over CEA [34]. 
It needs to be undertood that the neck base is not (with 
the cuttent technologies at least) the area for any routine 
percutaneous asscess. This is due to the fundamental 
risks that – with a fully percutaneous approach – include 
the risk of CCA dissection with a ‘bad’ angle in particular 
(deep CCA location, short neck, examples oin 1A-c and 
1B-a/b), the risk of CCA posterior wall puncture, vagal 
nerve injury, and the neck uncontrollable haematoma 
with the consequences of CCA occlusion, thrombosis, 
and embolism.
Transcervical CAS does not require a long arteriotomy, 
avoids the course of all high-lying cranial nerves [4, 5], and 
it does not leave a long and visible scar with an increased 
risk of permanently altered skin sensation [3, 34]. Shorter 
balloon catheters (in case of the decision on endovascular 
rather than surgical CCA clamping) along shorter balloon/
stent delivery systems would be welcomed by operators 
using the transcervical access and it might facilitate fur-
ther penetration of the strategy. While the current (mark-
edly excessive for the trans-carotid route, cf. Figure 1) 
length of the catheters (including flow-reversal catheters) 
makes their use for transcervical CAS rather inconvenient 
(cf. Figure 1), it is our experience that the catheter use (in 
comparison to a direct through-the-access-sheath proce-
dure), appears to be associated with an increased access 
system stability. Customization (significant shortening) of 
the balloon catheters (for those who would prefer to take 
advantage of an increased system stability and would 
refer to perform endovascular rather than surgical CCA 
clamp) would be an advantage, similar to customization 
of the wires, and the balloon and stent delivery systems. 
The flow reversal circuit tubing should be no longer than 
needed to reduce resistance to flow. An important point 
on the operator skills and attention part is a high-level 
care that needs to be taken to ensure the lesion ‘no-
touch’ prior to establising flow reversal.
One fundamental contraindication to the use of the 
transcervical access in CAS is any significant athero-oc-
clusive disease at the anticipated level of CA cannula-
tion, another is short neck with a low CCA division [3, 5]. 
Other contraindications are any anatomic abnormalities 
overlying CA at the base of the neck. The disadvantage 
of open CCA cutdown offers, at the same time, the ad-
vantage (over any percutaneous approach with the cur-
rent techniques and devices) of a fully controlled vessel 
cannulation in the critical anatomic region and of a fully 
controlled artery access site closure. There is currently no 
other CCA closure that would be more controllable and 
effective than surgical closure.
The role of ECA clamping to prevent potential ECA-
ICA flow during CCA clamping remains a  highly debat-
ed and unresolved issue [3–5, 23, 24]. It is highly likely, 
however, that a robust flow reversal may make the role 
of ECA exclusion negligible. Although larger data series 
are needed, we have not excluded ECA in 3/4 of cases 
and there was absence of cerebral embolism despite 
the embolic material generated with lesion crossing and 
predilatation (Figure 2 B). Ensuring flow reversal robust-
ness points to the role of the sheath/catheter and tubing 
diameter that, if relatively small, may be corrected with 
syringe aspiration(s) (whose feasibility should always be 
ensured in carotid flow reversal) while it appears to have 
been rightly optimized in the EnRoute TCAR kit. 
In addition to a  high-level procedural safety, TCAR 
minimizes cranial nerve injury associated with carotid 
surgery [10, 11] that is one of the important drawbacks 
of CEA from the patient’s perspective [34]. Overall evi-
dence, inclusive of a significant proportion (≈30–60%) of 
30-day strokes occurring with 1st generation carotid stents 
post-procedurally in relation to on-going post-procedur-
al plaque embolism [27] (see CREST, CAPTURE, ICSS and 
other data reviewed recently in Ref. 8 and Ref. 12) is con-
sistent with (not unexpected) TCAR first-generation open-
cell stent inability to eliminate post-procedural strokes 
[10, 11, 26]. Conversely, the MicroNET-covered stent design 
shows an effective minimization of post-procedural em-
bolism [29] (that is a measure of the clinical stroke risk 
[35]) and elimination of post-procedural strokes [15–18, 
30, 31], suggesting that the transcervical flow reversal ap-
proach to CAS will need to incorporate advances in the 
carotid stent design that translate into improved peri- 
and post-procedural neurologic outcomes. 
Investigator-initiated TOP-GUARD Study (Carotid Ar-
tery Revascularization Using Transcarotid flOw Reversal 
Cerebral Protection And CGUARD MicroNET Embolic Pre-
vention Stent System To Reduce Strokes; NCT04547387) 
is effectively continuing recruitment. Another study – 
focused on post-procedural evaluation of the endovas-
cular carotid artery plaque sequestration and lumen 
reconstruction using intravascular ultrasound (CGuard 
OPTIMA: OPTIMAl endovascular exclusion of high-risk 
carotid plaque using the CGuard™ MicroNET-covered 
embolic prevention stent system in consecutive pa-
tients with symptoms or signs of carotid stenosis-relat-
ed brain injury: An intravascular ultrasound-controlled 
investigator-initiated multicentric multi-specialty study; 
NCT04234854) is close to completing recruitment. 
Conclusions
In this technical note expanded with clinical and 
imaging data in a  series of very high-risk patients, we 
report our recent experience in transcervical carotid ar-
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tery revascularization in neurologically symptomatic 
patients. We show how using routinely available vas-
cular surgery and endovascular angiology equipment 
and tools for transient flow reversal to protect the brain 
from intra-procedural embolism, paired with the use of 
MicroNET-covered embolic prevention stents to exclude 
the symptomatic plaque from the lumen, enable an ef-
fective restoration of normal anatomy with prevention 
of plaque-related embolism. Use of a plaque-insulating 
stent system overcomes limitations of 1st generation ca-
rotid stents, increasing the spectrum of carotid lesions 
routinely suitable for endovascular stent-assisted lumen 
reconstruction to include highly-emboligenic lesions for 
which CEA has been a historic first choice. As it is well 
known today that optimized medical therapy alone is not 
sufficient to effectively prevent strokes in relation to ath-
erosclerotic carotid stenosis, minimally-invasive and clin-
ically-effective peri-procedural and post-procedural pre-
vention of post-procedural cerebral embolism (and thus 
post-procedural stroke risk prevention), taken together 
with improved stroke risk stratification at the lesion and 
patient level, may soon transform the field of stroke pre-
vention in relation to carotid artery stenosis. It is clear to-
day that the transcervical flow reversal approach to CAS 
[3–5, 9–11, 29, 36], will need to incorporate advances in 
the carotid stent design that, as accumulating evidence 
shows, translate into improved peri- and post-procedural 
cerebral outcomes. 
Acknowledgments
We would like to acknowledge contributions from 
Ewa Węglarz RN MSc, Łukasz Tekieli MD PhD, and Adam 
Mazurek MD PhD. We are grateful for support from the 
John Paul II Hospital in Krakow Hybrid Room staff (Heads: 
Zbigniew Woszczyna MSc, Ewa Żądło RN MSc), our col-
leagues from the Anesthesia Teams (Head: Robert Musiał 
MD PhD), our diagnostic radiology team (Dr. Małgorzata 
Urbańczyk and Paweł Banyś MSc) and consulting stroke 
neurologists. We thank Paweł Kołacz MSc for his editorial 
assisstance.
This work was supported by the science fund of the 
John Paul II Hospital, Krakow, Poland (no. FN11/2020 
to PM).
Conflict of interest
MT: Proctoring/Consulting: Medtronic, Terumo. PM: 
Proctoring/Consulting: Abbott, InspireMD, Medtronic. 
PM serves on the European Society of Cardiology (ESC) 
Stroke Council Scientific Documents Task Force.
In 2018 the John Paul II Hospital in Krakow was cer-
tified as an international ‘TCAR Center of Excellence’. 
There have been no financial relationships (or other re-
lationships that might be perceived as creating a conflict 
of interest) of the authors with the TCAR EnRoute system 
manufacturer.
We are grateful to SilkRoad Medical (USA) for their 
unrestricted provision (until the COVID-19 pandemic) of 
their CE-marked TCAR systems (EnRoute) for our routine 
clinical use.
References
1. Musialek P, Hopf-Jensen S. Carotid artery revascularization for 
stroke prevention: a new era. J Endovasc Ther 2017; 24: 138-48.
2. Grunwald IQ, Reith W, Kühn AL, et al. Proximal protection with 
the Gore PAES can reduce DWI lesion size in high-grade stenosis 
during carotid stenting. EuroIntervention 2014; 10: 271-6.
3. Chang DW, Schubart PJ, Veith FJ, Zarins CK. A new approach to 
carotid angioplasty and stenting with transcervical occlusion 
and protective shunting: why it may be a better carotid artery 
intervention. J Vasc Surg 2004; 39: 994-1002. 
4. Criado E, Doblas M, Fontcuberta J, et al. Transcervical carotid ar-
tery angioplasty and stenting with carotid flow reversal: surgical 
technique. Ann Vasc Surg 2004; 18: 257-61.
5. Pipinos II, Johanning JM, Pham CN, et al. Transcervical approach 
with protective flow reversal for carotid angioplasty and stent-
ing. J Endovasc Ther 2005; 12: 446-53.
6. Pieniazek P, Musialek P, Dzierwa K, et al. Flow reversal for proxi-
mal neuroprotection during endovascular management of criti-
cal symptomatic carotid artery stenosis coexisting with ipsilat-
eral external carotid artery occlusion. J Endovasc Ther 2009; 16: 
744-51.
7. Wissgott C, Schmidt W, Brandt-Wunderlich C, et al. Clinical re-
sults and mechanical properties of the CGuard double-layered 
embolic protection stent. J Endovasc Ther 2017; 24: 130-7.
8. Musiałek P, Roubin GS. Double-layer carotid stents: from the clin-
ical need, through a stent-in-stent strategy, to effective plaque 
isolation… the Journey Toward Safe Carotid Revascularization 
using the endovascular route. J Endovasc Ther 2019; 26: 572-7. 
9. Leal I, Orgaz A, Flores Á, et al. A diffusion-weighted magnetic 
resonance imaging-based study of transcervical carotid stenting 
with flow reversal versus transfemoral filter protection. J Vasc 
Surg 2012; 56: 1585-90.
10. Kashyap VS, Schneider PA, Foteh M, et al. Early outcomes in the 
ROADSTER 2 study of transcarotid artery revascularization in 
patients with significant carotid artery disease. Stroke 2020; 51: 
2620-9. 
11. Liang P, O’Donnell TFX, Cronenwett JL, et al. Vascular quality 
initiative risk score for 30-day stroke or death following tran-
scarotid artery revascularization. J Vasc Surg 2020; S0741-
5214(20)32279-5 (epub ahead of print).
12. Musiałek P, Hopkins LN, Siddiqui AH. One swallow does not 
a summer make but many swallows do: accumulating clinical 
evidence for nearly-eliminated peri-procedural and 30-day com-
plications with mesh-covered stents transforms the carotid re-
vascularisation field. Adv Interv Cardiol 2017; 13: 95-106.
13. Nikas D, Reith W, Schmidt A, et al. Prospective, multicenter Euro-
pean study of the GORE flow reversal system for providing neu-
roprotection during carotid artery stenting. Catheter Cardiovasc 
Interv 2012; 80: 1060-8.
14. Pieniazek P, Musialek P, Kablak-Ziembicka A, et al. Carotid artery 
stenting with patient- and lesion-tailored selection of the neuro-
protection system and stent type: early and 5-year results from 
a prospective academic registry of 535 consecutive procedures 
(TARGET-CAS). J Endovasc Ther 2008; 15: 249-62. 
Mariusz Trystuła et al. MicroNET stent and transcervical revascularization
506 Advances in Interventional Cardiology 2020; 16, 4 (62)
15. Musialek P, Mazurek A, Trystula M, et al. Novel PARADIGM in 
carotid revascularisation: prospective evaluation of All-com-
er peRcutaneous cArotiD revascularisation in symptomatic 
and Increased-risk asymptomatic carotid artery stenosis using 
CGuard™ MicroNet-covered embolic prevention stent system. 
EuroIntervention 2016; 12: e658-70.
16. Schofer J, Musiałek P, Bijuklic K, et al. A prospective, multicenter 
study of a novel mesh-covered carotid stent: the CGuard CAREN-
ET Trial (Carotid Embolic Protection Using MicroNET). JACC Car-
diovasc Interv 2015; 8: 1229-34.
17. Mazurek A, Partyka L, Trystula M, et al. Highly-calcific carotid 
lesions endovascular management in symptomatic and in-
creased-stroke-risk asymptomatic patients using the CGuard™ 
dual-layer carotid stent system: analysis from the PARADIGM 
study. Catheter Cardiovasc Interv 2019; 94: 149-56.
18. Mazurek A, Boratynska A, Malinowski KP, et al. MicroNET-cov-
ered stents for embolic prevention in patients undergoing ca-
rotid revascularisation: twelve-month outcomes from the PARA-
DIGM study. EuroIntervention 2020; 16: e950-2.
19. Mazurek A, Bugurov S, Musialek P. Short-term double lay-
er mesh stent patency for emergent or elective carotid artery 
stenting: a single center experience. Stroke 2019; 50: e433-4.
20. Tekieli Ł, Musiałek P, Kabłak-Ziembicka A, et al. Severe, recurrent 
in-stent carotid restenosis: endovascular approach, risk factors. 
Results from a prospective academic registry of 2637 consecu-
tive carotid artery stenting procedures (TARGET-CAS). Adv Interv 
Cardiol 2019; 15: 465-71.
21. Musialek P, Stabile E. Residual plaque prolapse with novel du-
al-layer carotid stents: is it mesh-covered or not? EuroInterven-
tion 2017; 13: 1266-8. 
22. Badacz R, Przewłocki T, Karch I, et al. Low prevalence of collateral 
cerebral circulation in the circle of Willis in patients with severe 
carotid artery stenosis and recent ischemic stroke. Adv Interv 
Cardiol 2015; 11: 312-7.
23. Ohki T, Parodi J, Veith FJ, et al. Efficacy of a proximal occlusion 
catheter with reversal of flow in the prevention of embolic 
events during carotid artery stenting: an experimental analysis. 
J Vasc Surg 2001; 33: 504-9.
24. Ouriel K, Greenberg RK, Sarac TP. Hemodynamic conditions at 
the carotid bifurcation during protective common carotid occlu-
sion. J Vasc Surg 2001; 34: 577-80. 
25. Badacz R, Kabłak-Ziembicka A, Urbańczyk-Zawadzka M, et al. 
Magnetic resonance imaging and clinical outcome in patients 
with symptomatic carotid artery stenosis after carotid artery re-
vascularization. Adv Interv Cardiol 2017; 13: 225-32.
26. Criado E, Fontcuberta J, Orgaz A, et al. Transcervical carotid 
stenting with carotid artery flow reversal: 3-year follow-up of 
103 stents. J Vasc Surg. 2007; 46: 864-9.
27. Schofer J, Arendt M, Tübler T, et al. Late cerebral embolization 
after emboli-protected carotid artery stenting assessed by se-
quential diffusion-weighted magnetic resonance imaging. JACC 
Cardiovasc Interv 2008; 1: 571-7.
28. Kotsugi M, Takayama K, Myouchin K, et al. Carotid artery stent-
ing: investigation of plaque protrusion incidence and prognosis. 
JACC Cardiovasc Interv 2017; 10: 824-31.
29. Karpenko A, Ignatenko P, Bugurov S. Randomized controlled trial 
of conventional versus Micronet-covered stent use in percuta-
neous neuroprotected carotid artery revascularization: peri-pro-
cedural and 30-day diffusion-weighted magnetic resonance 
imaging and clinical outcomes. https://media.pcronline.com/
diapos/PCReCourse2020/300-20200625_1610_Hotline_and_In-
novation_Channel_Ignatenko_Pavel_0000_(645)/MainRecord.
mp4 EuroPCR 2020 Late-Breaking Clinical Trial. (accessed 30 
November 2020).
30. Stabile E, de Donato G, Musialek P, et al. Use of dual-layered 
stents in endovascular treatment of extracranial stenosis of the 
internal carotid artery: results of a patient-based meta-analysis 
of 4 clinical studies. JACC Cardiovasc Interv 2018; 11: 2405-11.
31. Stabile E, de Donato G, Musialek P, et al. Use of dual-layered 
stents for carotid artery angioplasty: 1-year results of a  pa-
tient-based meta-analysis. JACC Cardiovasc Interv 2020; 13: 
1709-15.
32. Musialek P, Dabrowski W, Mazurek A, et al. Quantitative virtu-
al histology for in vivo evaluation of human atherosclerosis – 
a plaque biomechanics-based novel image analysis algorithm: 
validation and applications to atherosclerosis research. In: Ba-
locco S (ed.). Intravascular Ultrasound: From Acquisition to Ad-
vanced Quantitative Analysis. Elsevier 2000.
33. Piątek J, Kędziora A, Dzierwa K, et al. Hybrid one-day coronary 
artery bypass grafting and carotid artery stenting – cardiac sur-
geons’ perspective on the procedure’s safety. Adv Interv Cardiol 
2018; 14: 99-102.
34. Trystuła M, Tomaszewski T, Pąchalska M. Health-related quality 
of life in ischaemic stroke survivors after carotid endarterecto-
my (CEA) and carotid artery stenting (CAS): confounder-con-
trolled analysis. Adv Interv Cardiol 2019; 15: 226-33.
35. Traenka C, Engelter ST, Brown MM, et al. Silent brain infarcts 
on diffusion-weighted imaging after carotid revascularisation: 
a surrogate outcome measure for procedural stroke? A system-
atic review and meta-analysis. Eur Stroke J 2019; 4: 127-43.
36. Wang SK, Severance S, Westin GG, et al. Perioperative and 1-year 
transcarotid revascularization outcomes in symptomatic pa-
tients. J Vasc Surg 2020; 72: 2047-53.
